Thomas Ulmer
Director/Miembro de la Junta en Aravax Pty Ltd. .
Perfil
Thomas Ulmer is a Non-Executive Director at Aravax Pty Ltd.
He was previously a Co-Managing Director at Immatics Biotechnologies GmbH from 2018 to 2020 and Head of Planning, Forecasting & Resource Allocation at Merck KGaA from 2012 to 2016.
He also served as Chief Financial Officer at Immatics NV.
Ulmer holds an MBA from the University of Giessen.
Cargos activos de Thomas Ulmer
Empresas | Cargo | Inicio |
---|---|---|
Aravax Pty Ltd.
Aravax Pty Ltd. BiotechnologyHealth Technology Aravax Pty Ltd. develops treatments for peanut allergies. The company was founded in May 2015 and is headquartered in Melbourne, Australia. | Director/Miembro de la Junta | 01/11/2020 |
Antiguos cargos conocidos de Thomas Ulmer.
Empresas | Cargo | Fin |
---|---|---|
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Director Ejecutivo | 12/02/2020 |
MERCK KGAA | Corporate Officer/Principal | 01/07/2016 |
IMMATICS N.V. | Director Financiero/CFO | - |
Formación de Thomas Ulmer.
University of Giessen | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
IMMATICS N.V. | Health Technology |
MERCK KGAA | Health Technology |
Empresas privadas | 2 |
---|---|
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
Aravax Pty Ltd.
Aravax Pty Ltd. BiotechnologyHealth Technology Aravax Pty Ltd. develops treatments for peanut allergies. The company was founded in May 2015 and is headquartered in Melbourne, Australia. | Health Technology |
- Bolsa de valores
- Insiders
- Thomas Ulmer